New technologies in using recombinant attenuated salmonella vaccine vectors

Roy Curtiss, Wei Xin, Yuhua Li, Wei Kong, Soo Young Wanda, Bronwyn Gunn, Shifeng Wang

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Recombinant attenuated Salmonella vaccines (RASVs) have been constructed to deliver antigens from other pathogens to induce immunity to those pathogens in vaccinated hosts. The attenuation means should ensure that the vaccine survives following vaccination to colonize lymphoid tissues without causing disease symptoms. This necessitates that attenuation and synthesis of recombinant gene encoded protective antigens do not diminish the ability of orally administered vaccines to survive stresses encountered in the gastrointestinal tract. We have eliminated these problems by using RASVs with regulated delayed expression of attenuation and regulated delayed synthesis of recombinant antigens. These changes result in RASVs that colonize effector lymphoid tissues efficiently to serve as "factories" to synthesize protective antigens that induce higher protective immune responses than achieved when using previously constructed RASVs. We have devised a biological containment system with regulated delayed lysis to preclude RASV persistence in vivo and survival if excreted. Attributes were added to reduce the mild diarrhea sometimes experienced with oral live RASVs and to ensure complete safety in newborns. These collective technologies have been used to develop a novel, low-cost, RASV-synthesizing, multiple-protective Streptococcus pneumoniae antigens that will be safe for newborns/infants and will induce protective immunity to diverse S. pneumoniae serotypes after oral immunization.

Original languageEnglish (US)
Pages (from-to)255-270
Number of pages16
JournalCritical Reviews in Immunology
Volume30
Issue number3
StatePublished - 2010

Fingerprint

Salmonella Vaccines
Attenuated Vaccines
Synthetic Vaccines
Technology
Antigens
Lymphoid Tissue
Streptococcus pneumoniae
Immunity
Vaccines
Newborn Infant
Containment of Biohazards
Gastrointestinal Tract
Diarrhea
Immunization
Vaccination
Safety
Costs and Cost Analysis

Keywords

  • Antigen synthesis
  • Biological containment
  • Delayed
  • Delayed attenuation or attenuation
  • Recombinant vaccines
  • Salmonella
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Curtiss, R., Xin, W., Li, Y., Kong, W., Wanda, S. Y., Gunn, B., & Wang, S. (2010). New technologies in using recombinant attenuated salmonella vaccine vectors. Critical Reviews in Immunology, 30(3), 255-270.

New technologies in using recombinant attenuated salmonella vaccine vectors. / Curtiss, Roy; Xin, Wei; Li, Yuhua; Kong, Wei; Wanda, Soo Young; Gunn, Bronwyn; Wang, Shifeng.

In: Critical Reviews in Immunology, Vol. 30, No. 3, 2010, p. 255-270.

Research output: Contribution to journalArticle

Curtiss, R, Xin, W, Li, Y, Kong, W, Wanda, SY, Gunn, B & Wang, S 2010, 'New technologies in using recombinant attenuated salmonella vaccine vectors', Critical Reviews in Immunology, vol. 30, no. 3, pp. 255-270.
Curtiss, Roy ; Xin, Wei ; Li, Yuhua ; Kong, Wei ; Wanda, Soo Young ; Gunn, Bronwyn ; Wang, Shifeng. / New technologies in using recombinant attenuated salmonella vaccine vectors. In: Critical Reviews in Immunology. 2010 ; Vol. 30, No. 3. pp. 255-270.
@article{44c6dc91eff44d99b9735a1909ebc81f,
title = "New technologies in using recombinant attenuated salmonella vaccine vectors",
abstract = "Recombinant attenuated Salmonella vaccines (RASVs) have been constructed to deliver antigens from other pathogens to induce immunity to those pathogens in vaccinated hosts. The attenuation means should ensure that the vaccine survives following vaccination to colonize lymphoid tissues without causing disease symptoms. This necessitates that attenuation and synthesis of recombinant gene encoded protective antigens do not diminish the ability of orally administered vaccines to survive stresses encountered in the gastrointestinal tract. We have eliminated these problems by using RASVs with regulated delayed expression of attenuation and regulated delayed synthesis of recombinant antigens. These changes result in RASVs that colonize effector lymphoid tissues efficiently to serve as {"}factories{"} to synthesize protective antigens that induce higher protective immune responses than achieved when using previously constructed RASVs. We have devised a biological containment system with regulated delayed lysis to preclude RASV persistence in vivo and survival if excreted. Attributes were added to reduce the mild diarrhea sometimes experienced with oral live RASVs and to ensure complete safety in newborns. These collective technologies have been used to develop a novel, low-cost, RASV-synthesizing, multiple-protective Streptococcus pneumoniae antigens that will be safe for newborns/infants and will induce protective immunity to diverse S. pneumoniae serotypes after oral immunization.",
keywords = "Antigen synthesis, Biological containment, Delayed, Delayed attenuation or attenuation, Recombinant vaccines, Salmonella, Vaccine",
author = "Roy Curtiss and Wei Xin and Yuhua Li and Wei Kong and Wanda, {Soo Young} and Bronwyn Gunn and Shifeng Wang",
year = "2010",
language = "English (US)",
volume = "30",
pages = "255--270",
journal = "Critical Reviews in Immunology",
issn = "1040-8401",
publisher = "Begell House Inc.",
number = "3",

}

TY - JOUR

T1 - New technologies in using recombinant attenuated salmonella vaccine vectors

AU - Curtiss, Roy

AU - Xin, Wei

AU - Li, Yuhua

AU - Kong, Wei

AU - Wanda, Soo Young

AU - Gunn, Bronwyn

AU - Wang, Shifeng

PY - 2010

Y1 - 2010

N2 - Recombinant attenuated Salmonella vaccines (RASVs) have been constructed to deliver antigens from other pathogens to induce immunity to those pathogens in vaccinated hosts. The attenuation means should ensure that the vaccine survives following vaccination to colonize lymphoid tissues without causing disease symptoms. This necessitates that attenuation and synthesis of recombinant gene encoded protective antigens do not diminish the ability of orally administered vaccines to survive stresses encountered in the gastrointestinal tract. We have eliminated these problems by using RASVs with regulated delayed expression of attenuation and regulated delayed synthesis of recombinant antigens. These changes result in RASVs that colonize effector lymphoid tissues efficiently to serve as "factories" to synthesize protective antigens that induce higher protective immune responses than achieved when using previously constructed RASVs. We have devised a biological containment system with regulated delayed lysis to preclude RASV persistence in vivo and survival if excreted. Attributes were added to reduce the mild diarrhea sometimes experienced with oral live RASVs and to ensure complete safety in newborns. These collective technologies have been used to develop a novel, low-cost, RASV-synthesizing, multiple-protective Streptococcus pneumoniae antigens that will be safe for newborns/infants and will induce protective immunity to diverse S. pneumoniae serotypes after oral immunization.

AB - Recombinant attenuated Salmonella vaccines (RASVs) have been constructed to deliver antigens from other pathogens to induce immunity to those pathogens in vaccinated hosts. The attenuation means should ensure that the vaccine survives following vaccination to colonize lymphoid tissues without causing disease symptoms. This necessitates that attenuation and synthesis of recombinant gene encoded protective antigens do not diminish the ability of orally administered vaccines to survive stresses encountered in the gastrointestinal tract. We have eliminated these problems by using RASVs with regulated delayed expression of attenuation and regulated delayed synthesis of recombinant antigens. These changes result in RASVs that colonize effector lymphoid tissues efficiently to serve as "factories" to synthesize protective antigens that induce higher protective immune responses than achieved when using previously constructed RASVs. We have devised a biological containment system with regulated delayed lysis to preclude RASV persistence in vivo and survival if excreted. Attributes were added to reduce the mild diarrhea sometimes experienced with oral live RASVs and to ensure complete safety in newborns. These collective technologies have been used to develop a novel, low-cost, RASV-synthesizing, multiple-protective Streptococcus pneumoniae antigens that will be safe for newborns/infants and will induce protective immunity to diverse S. pneumoniae serotypes after oral immunization.

KW - Antigen synthesis

KW - Biological containment

KW - Delayed

KW - Delayed attenuation or attenuation

KW - Recombinant vaccines

KW - Salmonella

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77951004550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951004550&partnerID=8YFLogxK

M3 - Article

C2 - 20370633

AN - SCOPUS:77951004550

VL - 30

SP - 255

EP - 270

JO - Critical Reviews in Immunology

JF - Critical Reviews in Immunology

SN - 1040-8401

IS - 3

ER -